Navigation Links
Use Of Cryoablation For Treatment Of Breast Cancer Shows Promising Results
Date:5/7/2013

CHICAGO, May 7, 2013 /PRNewswire/ -- Dr. Eisuke Fukuma has treated 58 breast cancer patients with cryoablation over the last 6 years under a research protocol at Kameda Medical Center in Japan.  As of today, none of the patients have had a tumor reoccur or distant metastases. By this non-surgical treatment, Dr. Fukuma's patients avoid the risks and potential cosmetic impact of major breast cancer surgery.  The fact that none have had recurrences, suggests that, with further study, Cryoablation may offer significant, minimally-invasive breast health options.

(Photo: http://photos.prnewswire.com/prnh/20130507/CL09547)

Cryoablation is the technique of using extreme cold to destroy tissue.  It has been used for years in medical applications like dermatology, kidney, prostate and liver to treat both cancerous and non-cancerous tumors.

Eisuke Fukuma , MD, PhD, is Chairman of Breast Center at Kameda Medical Center in Kamogawa  City, Chiba, Japan.  Since 2006, his team has been developing cryoablation under image-guidance as a nonsurgical treatment for small breast cancer.

Dr. Fukuma's most recent 20 patients added to the clinical trial were treated using the IceSense3 Cryoablation system from IceCure Medical. While mainstream cancer treatment still requires significant research, the IceSense3 system is widely available in the US for the treatment of benign breast disease.  The procedure usually takes about 10-15 minutes; with no pain and virtually no scar (no sutures are required). As with a needle biopsy, many women can return to work or their normal activity quickly.

Dr. Fukuma previewed his next steps in research, which include expanding his research for larger tumors using the IceSense3, to a packed room of physicians and researchers at the 2013 conference of the American Society of Breast Surgeons (ASBrS).  To determine if nonsurgical cryoablation is an acceptable treatment for patients with small breast cancer, "we have to study a larger number of patients for a longer time period," remarks Dr. Fukuma.

Because of its procedural, clinical, and cosmetic results, Cryoablation garnered high level of attention at the conference.  Author of several pivotal studies on Cryoablation of benign tumors, Dr. Cary Kaufman also spoke about its use in breast cancer, adding that it has potential immunological benefits.

"We are extremely excited with the results presented by Dr. Fukuma," stated Hezi Himelfarb , President and CEO of IceCure Medical. "IceSense3 cryoablation system will continue to have major role in Dr. Fukuma's study towards providing less invasive and better cosmetic options for patients."

The IceSense3™ Cryoablation System was designed for efficient and effective treatment of breast tumors. The system has 510k FDA approval for benign and malignant breast disease.

About IceCure Medical

IceCure Medical, Inc.is a medical device company focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's health. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. To learn more about IceCure and Cryoablation for Breast Disease, please find us on the web at www.IceCure-Medical.com.  To learn about patient advocacy efforts follow us @CoverCryo on Twitter and BreastHealthOptions on Facebook.

For more information, contact
Will Irby
IceCure Medical, Inc.
(901) 237-4630
wirby@icecure-medical.com


'/>"/>
SOURCE IceCure Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
2. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
3. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
4. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
5. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
6. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
7. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
8. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
9. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
10. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... , ... Only two months after the official release of The Private Collection ... XO Private has initiated a second print-run of its lavish luxury travel coffee table ... when open, weighs in at more than six kilos, retails at EUR 1,000 per ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... In the ... to be a top priority because it’s not if you will be attacked, but ... especially when it comes to digital health care. , Improvements in auditing and monitoring ...
(Date:2/24/2017)... ... ... The California State University Institute for Palliative Care is pleased ... palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic Palliative ... Sept. 28 and 29, 2017, on the campus of California State University San Marcos. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, a national ... , media relations, social media, content marketing and SEO, is now offering direct, ... an intuitive marketing automation platform. , Rosica will now offer the platform to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
Breaking Medicine News(10 mins):